Archive for I

An Open-Label Phase 1b Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

A first-in-human Phase I, non-randomized, open-label, multi-center dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solid tumors expressing B7-H6

A Phase I, First in Human, Dose-Escalation Study of UCT-03-008 in Participants with Advanced Solid Tumors

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients with Advanced or Recurrent Solid Tumors

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

A Phase 1 Open-label, Multicenter, Dose-Ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients with HER2-Expressing Advanced Solid Tumors

« Older Entries
Newer Entries »